IMCR
HEALTHCAREImmunocore Holdings plc
$30.73+1.89 (+6.55%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IMCR Today?
No stock-specific AI insight has been generated for IMCR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$27.44$40.71
$30.73
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-0.56
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume330K
Avg Volume (10D)—
Shares Outstanding50.9M
IMCR News
20 articles- A Look At Immunocore (IMCR) Valuation After Strong Q1 2026 Results And New KIMMTRAK Survival DataYahoo Finance·May 8, 2026
- Immunocore (IMCR) Is Up 10.1% After Q1 Profitability Jumps On Higher Revenue And EfficiencyYahoo Finance·May 7, 2026
- Immunocore reports first quarter financial results and provides a business updateYahoo Finance·May 6, 2026
- KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaGlobeNewswire Inc.·Apr 19, 2026
- Immunocore Details KIMMTRAK Growth, TCR Platform and Key Readouts at Needham ConferenceMarketbeat·Apr 14, 2026
- Immunocore to present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 6, 2026
- A Look At Immunocore (IMCR) Valuation After Jefferies Downgrade And Kimmtrak Growth ConcernsYahoo Finance·Mar 28, 2026
- Jefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a $33 Price TargetYahoo Finance·Mar 25, 2026
- Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meetingYahoo Finance·Mar 17, 2026
- Qualcomm, Adobe downgraded: Wall Street's top analyst callsYahoo Finance·Mar 16, 2026
- Immunocore to present at upcoming investor conferencesYahoo Finance·Mar 3, 2026
- Is It Time To Revisit Immunocore Holdings (IMCR) After Recent Pipeline Progress?Yahoo Finance·Mar 1, 2026
- Immunocore Q4 Earnings Call HighlightsMarketbeat·Feb 25, 2026
- Immunocore Holdings PLC (IMCR) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ...Yahoo Finance·Feb 25, 2026
- JAZZ Stock Rises as Q4 Earnings & Sales Top ExpectationsYahoo Finance·Feb 25, 2026
- RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock UpYahoo Finance·Feb 25, 2026
- Immunocore (IMCR) Q4 2025 Earnings Call TranscriptMotley Fool·Feb 25, 2026
- Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/YYahoo Finance·Feb 25, 2026
- Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/YYahoo Finance·Feb 25, 2026
- Immunocore reports fourth quarter and full year 2025 financial results and provides a business updateYahoo Finance·Feb 25, 2026
All 20 articles loaded
Price Data
Open$28.69
Previous Close$28.84
Day High$29.59
Day Low$27.65
52 Week High$40.71
52 Week Low$27.44
52-Week Range
$27.44$40.71
$30.73
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-0.56
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume330K
Avg Volume (10D)—
Shares Outstanding50.9M
About Immunocore Holdings plc
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—